HRE A.I CyberSecurity Scoring
14/05/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Hamilton Robotics EMEA in 2026.
No incidents recorded for Hamilton Robotics EMEA in 2026.
No incidents recorded for Hamilton Robotics EMEA in 2026.
Biotechnology Research
At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
Latest updates, reports, and threat intel affecting the global network.
MojoX::Authentication versions before 0.006 for Perl allow SAML authentication bypass because parse_assertion builds Net::SAML2::Binding::POST without a trust anchor. parse_assertion in MojoX::Authentication::Model::SAML2 calls Net::SAML2::Binding::POST->new with no cacert, cert_text or anchors argument, then passes the returned XML to Net::SAML2::Protocol::Assertion->new_from_xml with the IdP signing certificate as cacert. In Net::SAML2 before 0.86 that certificate guards only encrypted assertions, so the signature on an unencrypted assertion is checked against the certificate the response itself carries. An attacker starts a SAML login, then posts a response signed with a certificate of their own. The audience, InResponseTo and timestamp checks that follow are all satisfiable by the attacker, so the response authenticates any NameID it carries.
A weakness has been identified in itsourcecode Sales and Inventory System 1.0. Affected by this vulnerability is an unknown functionality of the file /pages/sup_del.php?type=supplier. Executing a manipulation of the argument ID can lead to sql injection. The attack may be performed from remote. The exploit has been made available to the public and could be used for attacks.
A security flaw has been discovered in mwiede jsch up to 2.28.5. Affected is the function getRevokedKeys of the file src/main/java/com/jcraft/jsch/KnownHosts.java. Performing a manipulation of the argument known_hosts results in improper check for certificate revocation. The attack is possible to be carried out remotely. The attack is considered to have high complexity. The exploitability is told to be difficult. The exploit has been released to the public and may be used for attacks. Upgrading to version 2.28.6 is able to address this issue. The patch is named 194a2f76a5c0f1c3f778565be3fd66bcafc42d23. You should upgrade the affected component.
A security vulnerability has been detected in JeecgBoot up to 3.9.3. This vulnerability affects the function exportXls of the file jeecg-boot/jeecg-boot-module/jeecg-boot-module-airag/src/main/java/org/jeecg/modules/airag/llm/controller/AiragModelController.java. Such manipulation of the argument credential leads to improper access controls. It is possible to launch the attack remotely. The exploit has been disclosed publicly and may be used. Upgrading to version 3.9.5 is able to resolve this issue. The name of the patch is a2be896f753936956ee6863b632b8e5a0231345c. You should upgrade the affected component.
A weakness has been identified in valkey-io valkey up to 9.0.5/9.1.1. This affects the function kvstoreGetHashtable of the file src/kvstore.c. This manipulation of the argument didx causes out-of-bounds read. It is possible to initiate the attack remotely. The attack is considered to have high complexity. It is indicated that the exploitability is difficult. The exploit has been made available to the public and could be used for attacks. Patch name: 4691888e7fab3df128f0bde5750c9fde2ae552fa. To fix this issue, it is recommended to deploy a patch. Exploitation requires cluster mode plus attacker-controlled dump.rdb at startup (data-dir write access, replication feed, or a stored crafted RDB) - an attacker-position DoS at boot, not network pre-auth. The issue report was closed stating it "is worth fixing for the sake of memory safety… but I don't think it meets our bar for a security disclosure."
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.